TechMatrix Corporation and its consolidated subsidiary PSP Corporation have concluded a basic agreement on February 17, 2026, to acquire shares of Medmain Inc. for approximately 2.3 billion yen, aiming to hold a majority of voting rights and make it a consolidated subsidiary.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3762","jir_company_name":"TechMatrix Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/3762-20260217-01.pdf","jir_short_summary":"TechMatrix Corporation and its consolidated subsidiary PSP Corporation have concluded a basic agreement on February 17, 2026, to acquire shares of Medmain Inc. for approximately 2.3 billion yen, aiming to hold a majority of voting rights and make it a consolidated subsidiary.","jir_summary":"### Overview of the M&A\nTechMatrix Corporation and its consolidated subsidiary PSP Corporation have signed a basic agreement on February 17, 2026, to acquire shares of Medmain Inc. for approximately 2.3 billion yen, aiming to hold a majority of voting rights and make it a consolidated subsidiary. Medmain develops and operates AI software that supports digital pathological diagnosis. Through this share acquisition, TechMatrix will promote the development and commercialization of a digital pathological diagnosis platform highly integrated with AI technology. The expected percentage of voting rights owned after acquisition is over 70%.\n\n### Strategic Significance and Future Outlook\nThis initiative aligns with the TechMatrix Group's medium-term management plan emphasizing \"business domain expansion,\" \"growth in overseas markets,\" and \"creating businesses utilizing data.\" It aims to accelerate the promotion of DX in the pathology field within the medical systems business and expansion of AI-assisted image diagnosis services. The share transfer agreement is scheduled to be signed on April 1, 2026, with the execution expected by the end of April. Any impact on consolidated earnings will be disclosed promptly once confirmed.","jir_financial_highlights":"Acquisition Amount: Approximately 2.3 billion yen (Unknown)\nNumber of Shares to be Acquired: Unknown (Unknown)\nPercentage of Voting Rights Owned (Post-Acquisition): Over 70% (Unknown)","jir_category":"","jir_hashtags":"#TechMatrixCorporation, #M&A, #DigitalPathology, #AI, #MedicalSystems","jir_key_figures":"Acquisition Amount: Approximately 2.3 billion yen (planned)\nPercentage of Voting Rights Owned (Post-Acquisition): Over 70% (planned)\nScheduled Date for Share Transfer Agreement Signing: 2026-04-01","jir_meta_title":"TechMatrix Concludes Basic Agreement to Acquire Medmain Shares for Approximately 2.3 Billion Yen to Make It a Consolidated Subsidiary","jir_meta_description":"TechMatrix Corporation, together with its consolidated subsidiary PSP, has agreed to acquire shares of Medmain Inc. for approximately 2.3 billion yen to obtain majority voting rights and make it a consolidated subsidiary, strengthening the digital pathological diagnosis platform business utilizing AI technology.","jir_og_title":"TechMatrix Concludes Basic Agreement to Acquire Medmain Shares and Make It a Consolidated Subsidiary","jir_og_description":"TechMatrix Corporation aims to make Medmain Inc. a consolidated subsidiary through share acquisition and has concluded a basic agreement for approximately 2.3 billion yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9574,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-29815","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n